Price
No data yet.
Social Signal Score
80
5d
80
1 mentions
—
30d
80
1 mentions
—
60d
80
1 mentions
—
90d
80
1 mentions
—
news: 1
Revenue
$176.6KJun 2016Apr 2026
Company Profile
- CEO
- Andre Boulet
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 1.26
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.49
Financials
Revenue
$176.6K-91.5%Net Income
$-1.94MEBITDA
$-1.88M-3088.8%Free Cash Flow
$-731.9KEPS (diluted)
$-0.71Shares Outstanding (diluted)
2.77M+550.2%Operating Expenses
$0.00R&DSG&A
Cash & Debt
$719.7KCash & investmentsTotal debt
Quote
Day Range
$5.42 – $7.00
52-Week Range
$4.27 – $10.80
Volume
$100.00
Market Cap
$19.47M
50-Day Avg
$7.00
200-Day Avg
$7.66
Prev Close
$7.00
Open
$7.00
Valuation & Ratios
P/E Ratio
-8.51
EPS
$-1.76
P/B Ratio
5.60
P/S Ratio
2.17
Debt/Equity
0.02
Current Ratio
1.32
Dividend Yield
+0.0%
Gross Margin
+50.3%
Returns & Efficiency
Return on Equity
-65.8%
Return on Assets
-38.0%
FCF Yield
-2.5%
EV/EBITDA
-6.28
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $17.03M | $-4.34M | $-1.76 |
| 2024 | $17.82M | $-1.22M | $-0.50 |
| 2023 | $2.35M | $-4.60M | $-2.04 |
| 2022 | $2.31M | $-3.45M | $-1.74 |
| 2021 | $1.47M | $-3.35M | $-2.26 |
| 2020 | $2.14M | $-4.37M | $-3.62 |
| 2019 | $4.00M | $-2.69M | $-2.65 |
| 2018 | $3.17M | $-3.19M | $-3.06 |
| 2017 | $0.00 | $-4.38M | $-7.80 |
| 2016 | $0.00 | $-1.82M | $-4.35 |
| 2015 | $0.00 | $-89.0K | $-3.05 |
Valuation
DVHGFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130Sep 1Sep 1
Social Signal Score
80
5d
80
1 mentions
—
30d
80
1 mentions
—
60d
80
1 mentions
—
90d
80
1 mentions
—
news: 1
Mentions (1)
- Newsprnewswire.com·6h ago·Positive
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay Validated HPLC-MS, NMR and a validated cell-based biological potency assay using the U937 human cell line, with MIP-1β as a biological marker of Thykamine™'s anti-inflammatory activity, provide complementary chemical and biological measures of Thykamine™ and demonstrate reliable batch-to-batch consistency. QUEBEC, Sept.
View source ↗